138
138
Jun 28, 2021
06/21
by
CNBC
tv
eye 138
favorite 0
quote 0
shares of intelia surging after positive test results from the gene editing treatment let's get to meg for all of the details. >> melissa, we've seen crisper gene editing technology applied in some diseases like sickle cell and beta thalla, but those are different from intelia, they took patients cells out of thur bodies and gene edited them in the lab and returned them to patients. this data with intelia, which was released over the weekend, was the first time we've ever seen crisper geneticing technology be delivered systemically like other medicines. it was given an iv infusion treating attr and they were looking to see if they could do this delivery successfully and safely and knock down this protein that causes the problems in the disease and they did that on all three counts and 87% reduction was seen in that key protein so, mel, this is early days. this is only six patients in the phase one trial and only three on the higher dose but because of the proof of concept here, you are seeing not just intelia stock going up but other companies working in gene editing wellas from crispe
shares of intelia surging after positive test results from the gene editing treatment let's get to meg for all of the details. >> melissa, we've seen crisper gene editing technology applied in some diseases like sickle cell and beta thalla, but those are different from intelia, they took patients cells out of thur bodies and gene edited them in the lab and returned them to patients. this data with intelia, which was released over the weekend, was the first time we've ever seen crisper...
19
19
Jun 28, 2021
06/21
by
CNBC
tv
eye 19
favorite 0
quote 0
intelia, in a phase one trial, just reporting six patients worth of data over the weekend, showing this can be done and in fact in trying to edit that gene and not down this protein that causes problems in this very rare disease, this attr, they showed an 87% reduction of that problematic protein in the higher dose this really is a proof of concept for the entire field you're seeing other stocks that do gene etditing, beam therapeutics and verve up 25% there, really showing that people believe this can turn into real medicine you mentioned kathie wood, that etf she put together, focusing on the crisper names that one catching a lot of attention. on the flip side of this, el nylon is down on this news, it uses a different technology. investors may be factoring in common competition this is just phase one there is a long way to go. back to you. >> important day indeed. thank you for that, meg. >>> bitcoin rallying about 30,000, finance gets a boost we'll break down the latest crypto headlines that's up next >>> plus, watch microstrategy, the company continues to trade in sync with bitcoin
intelia, in a phase one trial, just reporting six patients worth of data over the weekend, showing this can be done and in fact in trying to edit that gene and not down this protein that causes problems in this very rare disease, this attr, they showed an 87% reduction of that problematic protein in the higher dose this really is a proof of concept for the entire field you're seeing other stocks that do gene etditing, beam therapeutics and verve up 25% there, really showing that people believe...
72
72
Jun 28, 2021
06/21
by
CNBC
tv
eye 72
favorite 0
quote 0
. >> thank you for correcting me on that, rob >>> shares of intelia therapeutics soaring after a positiveal of the gene editing treatment. also a big win for kathy wood. her arc management is the biggest shreead early in intellia if you wake up thinking about the market and want to make the right moves fast... get decision tech from fidelity. [ cellphone vibrates ] you'll get proactive alerts for market events before they happen... and insights on every buy and sell decision. with zero-commission online u.s. stock and etf trades. for smarter trading decisions, get decision tech from fidelity. for smarter trading decisions, this is dr. arnold t. petsworth, he's the owner of petsworth vetworld. business was steady, but then an influx of new four-legged friends changed everything. dr. petsworth welcomed these new patients. the only problem? more appointments meant he needed more space. that's when dr. petsworth turned to his american express business card, which offers spending potential that's built for his changing business needs. he used his card to furnish a new exam room and everyone wa
. >> thank you for correcting me on that, rob >>> shares of intelia therapeutics soaring after a positiveal of the gene editing treatment. also a big win for kathy wood. her arc management is the biggest shreead early in intellia if you wake up thinking about the market and want to make the right moves fast... get decision tech from fidelity. [ cellphone vibrates ] you'll get proactive alerts for market events before they happen... and insights on every buy and sell decision....
79
79
Jun 30, 2021
06/21
by
FBC
tv
eye 79
favorite 0
quote 0
specifically, intelia therapeuti cs and regeneron announced a gene editing breakthrough, no wonder these/3%, and the first-ever human study evaluating gene editing therapy the two companies were able to use the emerging technology to edit or snip out dna in babies to help avoid a serious illness later on in life. enter 23 and me. one of the leading consumer genetic testing kit companies on the market, and the only one that provides fda approved genetic health risk reports directly to consumers. joining us now, one of the world 's newest billionaires, 23 and me ceo and co-founder ann wojiski. ann, this is incredible stuff and if crispr technology can hopefully enable at some point on a grand scale editing out the genes that predispose people to diseases like alzheimers and diabetes, as i see it 23 and me is sort of the first step in flagging people that they are at risk of these diseases in the first place. how do you view the crispr breakthroughs? >> two things first and foremost look at part of a mission of 23 and me is just understanding the genome. like you can't edit unless you know
specifically, intelia therapeuti cs and regeneron announced a gene editing breakthrough, no wonder these/3%, and the first-ever human study evaluating gene editing therapy the two companies were able to use the emerging technology to edit or snip out dna in babies to help avoid a serious illness later on in life. enter 23 and me. one of the leading consumer genetic testing kit companies on the market, and the only one that provides fda approved genetic health risk reports directly to consumers....
127
127
Jun 28, 2021
06/21
by
FBC
tv
eye 127
favorite 0
quote 0
on flip side, intelia therapeutics, up 41%. partnership with regeneron. other gene editing companies are also higher today. so in a mixed market day, i showed you some nice winners. stuart: gene editing is becoming so sophisticated. lauren: i know. stuart: really contributing to medicine. lauren: that is the future. stuart: extraordinary. crisper, the one originally read dna, isn't it? i think the original. dow 30, a sense of the market. about 2/3 down, 1/3 up roughly speaking. dow winners at the top of that list is, there you go, intel up. apple, sales force, microsoft, amgen big names at tom of the dow winners list. s&p 500 winners list, etsy, i call them a chat key exchange that is not being nice to them, up 5%. nasdaq winners headed by nvidia. there you go again. about to do a four-for-one stock split. that always helps the company, the stock i should say. it is up another 4%. >>> there is this. making olympic at olympic trials, new jersey native, sydney mcglocklin shattering the world of 400-meter hurdles. what a development. we'll get into this. >>
on flip side, intelia therapeutics, up 41%. partnership with regeneron. other gene editing companies are also higher today. so in a mixed market day, i showed you some nice winners. stuart: gene editing is becoming so sophisticated. lauren: i know. stuart: really contributing to medicine. lauren: that is the future. stuart: extraordinary. crisper, the one originally read dna, isn't it? i think the original. dow 30, a sense of the market. about 2/3 down, 1/3 up roughly speaking. dow winners at...